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Introduction: Kallistatin levels in the circulation are reduced in patients with sepsis and liver disease. Transgenic
mice expressing kallistatin are resistant to lipopolysaccharide (LPS)-induced mortality. Here, we investigated the
effect of kallistatin on survival and organ damage in mouse models of established sepsis.
Methods: Mice were rendered septic by cecal ligation and puncture (CLP), or endotoxemic by LPS injection.
Recombinant human kallistatin was administered intravenously six hours after CLP, or intraperitoneally four hours
after LPS challenge. The effect of kallistatin treatment on organ damage was examined one day after sepsis
initiation, and mouse survival was monitored for four to six days.
Results: Human kallistatin was detected in mouse serum of kallistatin-treated mice. Kallistatin significantly reduced
CLP-induced renal injury as well as blood urea nitrogen, serum creatinine, interleukin-6 (IL-6), and high mobility
group box-1 (HMGB1) levels. In the lung, kallistatin decreased malondialdehyde levels and HMGB1 and toll-like
receptor-4 (TLR4) synthesis, but increased suppressor of cytokine signaling-3 (SOCS3) expression. Moreover, kallistatin
attenuated liver injury, serum alanine transaminase (ALT) levels and hepatic tumor necrosis factor-α (TNF-α) synthesis.
Furthermore, delayed kallistatin administration improved survival in CLP mice by 38%, and LPS-treated mice by 42%.
In LPS-induced endotoxemic mice, kallistatin attenuated kidney damage in association with reduced serum creatinine,
IL-6 and HMGB1 levels, and increased renal SOCS3 expression. Kallistatin also decreased liver injury in conjunction with
diminished serum ALT levels and hepatic TNF-α and TLR4 expression. In cultured macrophages, kallistatin through its
active site increased SOCS3 expression, but this effect was blocked by inhibitors of tyrosine kinase, protein kinase C
and extracellular signal-regulated kinase (ERK), indicating that kallistatin stimulates a tyrosine-kinase-protein kinase
C-ERK signaling pathway.
Conclusions: This is the first study to demonstrate that delayed human kallistatin administration is effective in
attenuating multi-organ injury, inflammation and mortality in mouse models of polymicrobial infection and
endotoxemia. Thus, kallistatin therapy may provide a promising approach for the treatment of sepsis in humans.Introduction
Sepsis is a systemic inflammatory response caused by
microbial infection or bacterial products, such as
lipopolysaccharide (LPS) [1]. Despite many years of
dedicated research, sepsis remains one of the most
frequent causes of mortality in critically ill patients,
and contributes to significant economic costs in the
United States [1-3]. Because numerous signaling cascades* Correspondence: chaoj@musc.edu
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matory mediators is not sufficient to arrest this process
[3]. Inflammation and multi-organ dysfunction are closely
associated with sepsis-induced lethality [4]. Sepsis is
mediated by early (tumor necrosis factor-α (TNF-α),
interleukin-6 (IL-6)) and late (high mobility group
box-1 (HMGB1)) inflammatory cytokines in response to
infection [1]. Although the underlying pathophysiology of
sepsis has not been completely elucidated, TNF-α and
HMGB1 upregulation is known to play a crucial role in
the systemic inflammatory response [5-7]. Moreover,
suppressor of cytokine signaling-3 (SOCS3), a feedbackis an Open Access article distributed under the terms of the Creative Commons
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response [8], has also been shown to be a key player in inhi-
biting NF-κB-mediated pro-inflammatory cytokine produc-
tion and HMGB1 release [9,10]. LPS stimulates SOCS3
expression in macrophages, possibly through activation of
protein kinase C (PKC), phosphoinositide 3-kinase
(PI3K) and extracellular signal-regulated kinase (ERK1/2)
[11,12]. Furthermore, SOCS3 deficiency was found to
promote inflammation in macrophages, whereas SOCS3
gene delivery reduced the mortality of mice with LPS-
induced endotoxic shock [9,13]. Thus, approaches that
broadly target the inhibition of systemic inflammation
could provide effective strategies for the treatment of
sepsis.
Kallistatin was first purified and characterized from
human plasma as a novel serine proteinase inhibitor
(serpin) and a specific tissue kallikrein inhibitor [14].
Kallistatin is an acidic glycoprotein with a pI of 4.6 and
a molecular weight of 58 kDa [14,15]. As an endogenous
protein, kallistatin exhibits pleiotropic effects in inhibiting
inflammation, apoptosis and oxidative stress in animal
models and cultured cells [16-21]. The normal plasma
level of kallistatin in healthy subjects, measured by a spe-
cific ELISA, is 22.1 ± 3.5 μg/ml [22]. Circulating kallistatin
levels are reduced in patients with septic syndrome and
liver disease, as well as in mice with LPS-induced endo-
toxemia [22,23]. Transgenic mice expressing rat kallistatin
display prolonged survival when subjected to endotoxic
shock [23]. Moreover, kallistatin SERPINA4 gene transfer
attenuates mortality, inflammation, and liver and skin
damage in mice with Gram-positive streptococcal infec-
tion [24]. Kallistatin competes with TNF-α binding to
cultured endothelial cells through its heparin-binding
domain, thereby antagonizing TNF-α-induced NF-κB
activation, pro-inflammatory gene expression and subse-
quent inflammatory response [21]. Likewise, kallistatin’s
heparin-binding site is essential for blocking HMGB1-
induced inflammatory gene expression in endothelial cells
[25]. Therefore, kallistatin is capable of inhibiting the
inflammatory responses of both early (TNF-α) and late
(HMGB1) cytokines. We recently reported that kallistatin
pre-treatment attenuated kidney injury, inflammatory
gene expression and mortality in cecal ligation and
puncture (CLP)-induced septic mice [25]. In this study, we
further investigated the effect and potential mechanism
of delayed kallistatin administration after onset of
sepsis on mortality and organ injury in mouse models
of polymicrobial sepsis and endotoxic shock.
Methods
Purification and characterization of recombinant human
kallistatin
Recombinant human kallistatin was secreted into the
serum-free medium of cultured human embryonic kidneycells (HEK293T), and culture medium was concentrated
by ammonium sulfate precipitation followed by nickel-
affinity and heparin-affinity chromatography as previously
described [25,26]. Human recombinant wild-type kallistatin,
heparin-binding site mutant kallistatin and active site
mutant kallistatin were purified from Escherichia coli
as previously described [26].
Cecal ligation and puncture-induced sepsis and survival
study
CD-1 mice (male, seven to eight-weeks-old; Harlan,
Indianapolis, IN, USA) were housed in a germ-free
environment. All procedures complied with the standards
for care and use of animal subjects as stated in the
National Research Council’s Guide for the Care and Use of
Laboratory Animals. The protocol for all animal studies
was approved by the Institutional Animal Care and Use
Committee at the Medical University of South Carolina
(approval number: ARC#3158). All surgery was performed
under anesthesia to minimize suffering. CLP was performed
as described previously [25]. Briefly, the cecum was ligated
at the colon juncture and then punctured twice with a
21-gauge needle. All animals were then fluid-resuscitated
subcutaneously with 0.8 ml normal sterile saline. The
sham operation was performed in the same way as CLP,
but without ligation and puncture of the cecum. Mice
were randomly assigned to one of four groups (n = 5 per
group): 1) sham group receiving phosphate-buffered saline
(PBS); 2) CLP control group receiving PBS; 3) CLP + KS3
group receiving 3 mg/kg body weight of kallistatin; or 4)
CLP + KS10 group receiving 10 mg/kg body weight of
kallistatin. Mice were injected intravenously with 0.1 ml
PBS or recombinant human kallistatin in 0.1 ml PBS six
hours after surgery. Mice (Harlan, Indianapolis, IN, USA)
were killed 24 hours after CLP, and serum and tissues
were collected for biochemical and histological analyses.
For the survival study, mice were randomly assigned to
one of three groups (n = 16 per group): 1) sham group re-
ceiving PBS; 2) CLP control group receiving PBS; or 3)
CLP + KS20 group receiving 20 mg/kg body weight of kal-
listatin. At six hours after CLP surgery, mice were
injected intravenously with 0.1 ml PBS or recombin-
ant kallistatin in 0.1 ml PBS. Mouse survival was
monitored every 24 hours for a total of six days.
Lipopolysaccharide-induced endotoxemia and survival
study
Endotoxemia was induced in CD-1 mice (male, seven to
eight-weeks-old) by intraperitoneal injection of LPS (15
mg/kg body weight; E. coli LPS 0111:B4; Sigma-Aldrich, St.
Louis, USA) dissolved in sterile saline. Mice were randomly
assigned to one of four groups (n = 6 per group): 1) control
group receiving sterile saline; 2) LPS control group receiving
sterile saline; 3) LPS + KS10 group receiving 10 mg/kg body
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20 mg/kg body weight of kallistatin. At four hours after
LPS injection, mice were injected intraperitoneally with
0.1 ml of sterile saline or recombinant kallistatin in 0.1 ml
sterile saline. Mice were sacrificed at 22 hours after LPS
challenge, and serum and tissues were collected for
biochemical and histological analyses. For the survival
study, mice were assigned to one of two groups (n = 16
per group): 1) LPS control group receiving sterile
saline; or 2) LPS + KS20 group receiving 20 mg/kg
body weight of kallistatin. Mice were injected intra-
peritoneally with 0.1 ml sterile saline or recombinant
kallistatin in 0.1 ml sterile saline four hours after LPS
injection. Mouse survival was monitored every 12
hours for a total of four days.
Measurements of kallistatin, blood urea nitrogen,
creatinine, TNF-α, IL-6, HMGB1, malondialdehyde and
alanine transaminase levels in serum
Human kallistatin levels in the serum were determined
by enzyme-linked immunosorbent assay (ELISA) specific
for human kallistatin [22]. Blood urea nitrogen (BUN)
and serum creatinine were measured with QuantiChrom
Urea and Creatinine Assay Kits (BioAssay Systems,
Hayward, CA, USA), respectively. Serum TNF-α levels
were determined by a mouse TNF-α ELISA kit (EMD
Millipore, Billerica, MA, USA). IL-6 levels in serum were
measured using a mouse IL-6 ELISA kit (eBioscience, San
Diego, CA, USA). Serum HMGB1 levels were determined
by a mouse HMGB1 ELISA kit (Antibodies-online Inc.,
Atlanta, GA, USA). The levels of lung malondialdehyde
(MDA) were determined as previously described [27].
Serum alanine transaminase (ALT) levels were measured
using an ALT colorimetric assay kit (Cayman Chemical
Company, Michigan, MI, USA).
Tissue staining
For histological studies, kidney and liver were fixed with
4% paraformaldehyde, dehydrated, embedded and cut
into 4-μm sections. Tissue sections were stained with
hematoxylin and eosin (H&E) for examination of mor-
phological damage.
Cell culture
Mouse macrophages (RAW264.7) were cultured in
Dulbecco’s modified Eagle’s medium (Gibco Invitrogen
Corporation, Carlsbad, CA, USA) supplemented with heat
inactivated 10% fetal bovine serum (Cellgro Mediatech
Inc., Herndon, VA, USA) and 2% penicillin/streptomycin
(BioWhittaker Inc., Walkersville, MD, USA) in 150 cm2
tissue culture flasks and maintained at 37°C in 5% CO2,
95% air. RAW264.7 cells within 20 passages were
used for experiments. Cells were pretreated with
PD98059 (ERK inhibitor, 10 μM), chelerythrine (PKCinhibitor, 1 μM) and genistein (tyrosine kinase inhibitor,
5 μM, Sigma-Aldrich, St. Louis, USA) for 30 minutes,
followed by stimulation with kallistatin (0.1 μM) for 12
hours. In another set of experiments, macrophages were
incubated with 0.05 μM of wild-type kallistatin, heparin-
mutant kallistatin or active site mutant kallistatin in the
presence of polymyxin B (10 μg/ml) for 12 hours.
Real-time reverse transcription-polymerase chain reaction
Total RNA was extracted from lung, kidney and liver tissues
and cultured macrophages with TRIzol® reagent (Invitrogen,
Carlsbad, CA, USA), following the manufacturer's protocol.
cDNA was synthesized with a High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA,
USA) according to the manufacturer’s instructions. Quanti-
tative real-time PCR was performed by Prism 7300 Real
Time PCR System (Applied Biosystems) using TaqMan
Gene Expression Master Mix (Applied Biosystems) in a final
reaction volume of 20 μl with each primer. The following
primers were purchased from Applied Biosystems: mouse
GAPDH (Mm 99999915_gl), mouse HMGB1 (Mm
00849805_gl), mouse TLR4 (Mm 00445274_m1), mouse
TNF-α (Mm 00443258_ml) and mouse SOCS3 (Mm
00545913_s1). A negative control without cDNA did not
produce any amplicons. Data were analyzed with 2−ΔΔCt
value calculation, using GAPDH for normalization.
Western blot analysis
Macrophages were lysed with ice-cold RIPA lysis buffer (10
mM Tris, pH 7.4, 1% Triton X-100, 150 mM NaCl, 1 mM
EGTA, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride,
1 μg/ml aprotinin, 1 μg/ml leupeptin and 1 μg/ml pepstatin
A, Sigma-Aldrich, St. Louis, USA). All lysed samples
were kept on ice for 30 minutes, and centrifuged for 10 mi-
nutes at 4°C at 12,000 g. The supernatant was collected
and stored at −20°C until further analysis. Cell lysates were
subjected to 10% SDS-PAGE and transferred onto a
polyvinylidene difluoride membrane. The membranes (GE
Heathcare, Waukesha, WI, USA) were blocked with 7%
milk in Tris-buffered saline-Tween 20 (TBST, 20 mM Tris,
500 mM NaCl, and 0.1% Tween 20) for one hour. After
washing with TBST twice, membranes were incubated with
primary antibody overnight at 4°C. The following primary
antibodies were used: polyclonal anti-phospho-p44/42
MAPK (ERK1/2) and polyclonal anti-p44/42 MAPK
(ERK1/2) (Cell Signaling, Boston, MA, USA). The mem-
branes were washed twice with TBST and incubated with
Peroxidase from horseradish (HRP) conjugated secondary
antibody (Cell Signaling, Boston, MA, USA) in blocking
buffer for one hour. After washing three times with
TBST, immunoreactive bands were visualized by incuba-
tion with ECL plus detection reagents (GE Healthcare,
Waukesha, WI, USA) for five minutes and exposure to
BioMax light film (Thermo Scientific, Waltham, MA,
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ImageJ2 software (National Institutes of Health, Bethesda,
MD, USA).
Statistical analysis
Data are expressed as means ± standard error of the mean
(SE). Statistical significance was determined by analysis of
variance (ANOVA) with Fisher’s probable least-squares dif-
ference test or log-rank (Mantel-Cox) test, using GraphPad
Prism software (GraphPad Software, Inc., La Jolla, CA, USA).
A value of P <0.05 was considered statistically significant.
Results
Kallistatin attenuates renal injury, blood urea nitrogen,
serum creatinine, IL-6 and HMGB1 levels in cecal ligation
and puncture mice
Human kallistatin (KS; 3 or 10 mg/kg) was injected
intravenously into mice six hours after CLP surgery.
Human kallistatin was detected in mouse serum at 24
hours after injection in the kallistatin-treated groups, but
not in the sham or CLP control groups (CLP + KS3:Figure 1 Delayed kallistatin treatment reduces renal injury and decreases b
high mobility group box-1 (HMGB1) levels in cecal ligation and puncture (C
examine renal histology (n = 4). The representative sections are shown at ×
and (E) HMGB1 were significantly decreased by kallistatin administration in
versus sham group; #P <0.05 versus CLP control group.160.5 ± 26.3 ng/ml, CLP + KS10: 639.6 ± 126.7 ng/ml;
n = 4). The effect of kallistatin on CLP-induced renal
injury was characterized by H&E staining at 24 hours
after CLP surgery (Figure 1A). Histological findings in the
sham group showed renal tubules with no damage. Di-
lated renal tubules and swollen tubular cells were ob-
served in the CLP control group, and slightly thickened
basement membranes of renal tubules were found in
CLP mice with kallistatin administration. BUN levels
were markedly increased in the CLP control group, but
significantly reduced by kallistatin administration (CLP
control: 64.1 ± 4.2 mg/dL, CLP + KS3: 33.7 ± 8.9 mg/
dL, CLP + KS10: 27.1 ± 4.8 mg/dL; n = 4, P <0.05;
Figure 1B). Kallistatin treatment also significantly de-
creased CLP-induced serum creatinine levels (CLP
control: 0.7 ± 0.03 mg/dL, CLP + KS3: 0.5 ± 0.05 mg/
dL, CLP + KS10: 0.4 ± 0.05 mg/dL; n = 4, P <0.05;
Figure 1C). Moreover, compared to the CLP control
group, kallistatin administration reduced serum levels
of IL-6 (CLP control: 19.9 ± 2.5 ng/ml, CLP + KS3:
7.0 ± 1.6 ng/ml, CLP + KS10: 5.5 ± 1.6 ng/ml; n = 3lood urea nitrogen (BUN), serum creatinine, interleukin-6 (IL-6) and
LP) mice. (A) H&E staining was performed on kidney sections to
200 magnification. Levels of (B) BUN, (C) serum creatinine, (D) IL-6
CLP mice (n = 3 to 4). Data are expressed as means ± SE. *P <0.05
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100.7 ± 23.7 ng/ml, CLP + KS3: 40.9 ± 16.3 ng/ml, CLP +
KS10: 49.6 ± 7.0 ng/ml; n = 4, P <0.05; Figure 1E).
Kallistatin decreases malondialdehyde, HMGB1 and TLR4
levels, but increases SOCS3 expression in the lungs of
cecal ligation and puncture mice
Kallistatin administration attenuated CLP-induced lipid
peroxidation as evidenced by reduced lung MDA levels
compared to the CLP control group (CLP + KS3: 63.1 ±
11.2% reduction, CLP + KS10: 67.8 ± 4.8% reduction;
n = 4, P <0.05; Figure 2A) Lung HMGB1 expression
was increased in the CLP control group, but significantly
reduced by kallistatin treatment (CLP + KS3: 37.6 ± 7.7%
reduction, CLP + KS10: 57.0 ± 5.9% reduction; n = 3,
P <0.05; Figure 2B). Kallistatin treatment also markedly
decreased CLP-induced lung TLR4 expression (CLP + KS3:
63.9 ± 15.9% reduction, CLP + KS10: 80.9 ± 4.6% reduc-
tion; n = 3, P <0.05; Figure 2C). Moreover, mice receiving
kallistatin treatment at the lower dose (KS3) exhibited a
significant increase in lung SOCS3 expression compared
with the sham group (CLP + KS3: 1.7 ± 0.1 fold; n = 3,
P <0.05; Figure 2D), whereas kallistatin administration
at the higher dose (KS10) further increased lung SOCS3 ex-
pression compared to the CLP control group (CLP + KS10:
1.8 ± 0.2 fold; n = 3, P <0.05; Figure 2D).Figure 2 Delayed kallistatin treatment reduces malondialdehyde (MDA), hi
expression, and increases suppressor of cytokine signaling-3 (SOCS3) expre
of (A) MDA, (B) HMGB1 and (C) TLR4 were significantly reduced in kallistatin-
increased SOCS3 expression compared to the sham group (n = 3). Data are e
CLP control group.Kallistatin reduces liver injury, serum alanine
transaminase levels and hepatic TNF-α expression in cecal
ligation and puncture mice
The effect of kallistatin on liver injury was evaluated
by H&E staining at 24 hours after polymicrobial
infection. As shown in Figure 3A, liver tissues from
the CLP control group showed swollen hepatocytes
and red blood cell infiltration, but the effects were
reversed after kallistatin treatment. Kallistatin admin-
istration decreased CLP-induced serum ALT levels
(CLP control: 186.8 ± 22.0 U/L, CLP + KS3: 101.1 ±
16.2 U/L, CLP + KS10: 48.5 ± 14.7 U/L; n = 3 to 4,
P <0.05; Figure 3B). Kallistatin administration also sig-
nificantly reduced CLP-induced hepatic TNF-α expression
(CLP + KS3: 49 ± 5.4% reduction, CLP + KS10: 63 ± 2.5%
reduction; n = 3, P <0.05; Figure 3C) compared to the
CLP control group.
Delayed kallistatin administration prolongs survival of
polymicrobial septic and endotoxemic mice
To determine the effect of kallistatin on CLP-induced
mortality, kallistatin (20 mg/kg) was injected intravenously
into mice at six hours after CLP surgery. A mortality study
was conducted and the survival of CLP mice was moni-
tored every 24 hours for a total of six days. Sham-operated
mice (n = 16) exhibited 100% survival. All CLP controlgh mobility group box-1 (HMGB1) and toll-like receptor-4 (TLR4)
ssion in lung tissue of cecal ligation and puncture (CLP) mice. Levels
treated mice (n = 3 to 4). (D) Kallistatin administration also significantly
xpressed as means ± SE. *P <0.05 versus sham group; #P <0.05 versus
Figure 3 Delayed kallistatin administration attenuated liver injury, serum alanine transaminase (ALT) levels and liver tumor necrosis factor-α
(TNF-α) expression in cecal ligation and puncture (CLP) mice. (A) H&E staining was performed on liver sections to examine liver histology
(n = 4). Representative sections are shown at ×200 magnification. (B) Serum ALT levels and (C) liver TNF-α expression were significantly
decreased in kallistatin-treated CLP mice (n = 3 to 4). Data are expressed as means ± SE. *P <0.05 versus sham group; #P <0.05 versus CLP
control group.
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administration (20 mg/kg) increased the survival rate
by 38% compared to CLP control mice (n = 16, P <0.05;
Figure 4A). To determine the effect of kallistatin on LPS-
induced mortality, sterile saline or kallistatin (20 mg/kg)
was injected intraperitoneally into mice four hours after
LPS injection (15 mg/kg). Mouse survival was monitored
every 12 hours for a total of four days. Treatment
with kallistatin significantly improved the survival rate by
42% compared to the LPS control mice (n = 16, P <0.05;
Figure 4B).Figure 4 Delayed kallistatin treatment improves survival in cecal ligation a
endotoxemic mice. (A) Mice receiving human kallistatin (20 mg/kg, KS20) p
period compared to CLP control mice (PBS group); sham-operated mice ex
(20 mg/kg, KS20) exhibited significantly reduced mortality rate during the o
versus CLP control group or LPS control group.Kallistatin reduces renal injury and serum creatinine,
TNF-α, IL-6 and HMGB1 levels, but increases renal SOCS3
expression in endotoxemic mice
Human kallistatin levels were detected in mouse serum
at 22 hours after LPS injection in the kallistatin-
treated groups (10 or 20 mg/kg), but not in the control or
LPS control groups (LPS + KS10: 1377 ± 141.5 ng/ml,
LPS + KS20: 2715 ± 176.3 ng/ml; n = 4 to 5). H&E
staining was performed to evaluate the effect of kallistatin
on LPS-induced kidney injury at 22 hours after LPS injec-
tion. As shown in Figure 5A, treatment with kallistatinnd puncture (CLP) mice and lipopolysaccharide (LPS)-induced
resented significantly reduced mortality during the observation
hibited 100% survival (n = 16). (B) Mice receiving human kallistatin
bservation period compared to LPS control mice (n = 16). *P <0.05
Figure 5 Delayed kallistatin treatment reduces renal injury, serum creatinine, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and high mobility
group box-1 (HMGB1) levels, and increases renal suppressor of cytokine signaling-3 (SOCS3) expression in endotoxemic mice. (A) H&E staining
was performed on kidney sections to examine histology (n = 4). The representative sections are shown at ×200 magnification. (B) Serum creatinine
levels were attenuated by kallistatin treatment. (C) TNF-α, (D) IL-6 and (E) HMGB1 levels in serum of kallistatin-treated mice were significantly lower
than that of the lipopolysaccharide (LPS) control mice. (F) Kallistatin treatment also significantly increased renal SOCS3 expression (n = 3 to 6). Data are
expressed as means ± SE. *P <0.05 versus control group; #P <0.05 versus LPS control group.
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infiltrated immune cells and reduced tubular injury in the
kidneys of mice injected with LPS. Kallistatin treatment
significantly lowered LPS-induced serum creatinine
levels (LPS control: 1.3 ± 0.2 mg/dL, LPS + KS10: 0.8 ±
0.1 mg/dL, LPS + KS20: 0.5 ± 0.1 mg/dL; n = 4 to 6,
P <0.05; Figure 5B). Compared to the LPS control
group, kallistatin administration markedly reduced
serum levels of TNF-α (LPS control: 122.4 ± 15.3 pg/ml,
LPS + KS10: 39.6 ± 5.8 pg/ml, LPS + KS20: 28.7 ±
5.9 pg/ml; n = 3 to 4, P <0.05; Figure 5C) and IL-6
(LPS control: 110.3 ± 18.7 ng/ml, LPS + KS10: 42.5 ±
16.1 ng/ml, LPS + KS20: 50.7 ± 16.1 ng/ml; n = 4 to 5,
P <0.05; Figure 5D). Moreover, kallistatin treatment
reduced LPS-induced elevation of serum HMGB1
levels (LPS control: 138 ± 35.1 ng/ml, LPS + KS10:
24.9 ± 15.9 ng/ml, LPS + KS20: 44.6 ± 17 ng/ml; n = 4,
P <0.05; Figure 5E). LPS challenge dramatically upregulatedrenal SOCS3 expression compared to the control group
(LPS control: 18.1 ± 0.9 fold; n = 3, P <0.05; Figure 5F), and
kallistatin administration further increased renal SOCS3 ex-
pression compared to the LPS control group (LPS + KS10:
1.5 ± 0.2 fold, LPS + KS20: 1.8 ± 0.2 fold; n = 3, P <0.05;
Figure 5F).
Kallistatin reduces liver injury, serum alanine
transaminase levels and TNF-α and TLR4 expression in
endotoxemic mice
H&E staining was performed to evaluate the effect of
kallistatin on LPS-induced liver injury at 22 hours after
LPS injection. As shown in Figure 6A, liver tissues from
the LPS control group contained cracks, fibrin deposits
and infiltrated red blood cells that were less frequent
in kallistatin-treated groups. Kallistatin treatment
attenuated LPS-induced serum ALT levels (LPS control:
54.9 ± 8.2 U/L, LPS + KS10: 26.5 ± 5.0 U/L, LPS + KS20:
Figure 6 Kallistatin treatment ameliorates liver injury, attenuates serum alanine transaminase (ALT) levels, and reduces tumor necrosis factor-α
(TNF-α) and toll-like receptor-4 (TLR4) expression in liver tissue of LPS-induced endotoxemic mice. (A) H&E staining was performed on liver
sections to examine histology (n = 4). The representative sections are shown at ×200 magnification. (B) Kallistatin administration reduces serum
ALT levels (n = 3 to 4). Liver mRNA levels of (C) TNF-α and (D) TLR4 were significantly decreased by kallistatin treatment (n = 3). *P <0.05 versus
control group; #P <0.05 versus LPS control group.
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administration also attenuated LPS-induced hepatic
TNF-α (LPS + KS10: 47 ± 3.2% reduction, LPS +
KS20: 56 ± 15.1% reduction; n = 3, P <0.05; Figure 6C)
and TLR4 expression (LPS + KS10: 43 ± 8.9% reduction,
LPS + KS20: 67 ± 4.5% reduction; n = 3, P <0.05;
Figure 6D) compared to the LPS control group.
Kallistatin via its active site induces SOCS3 expression
through tyrosine kinase-PKC-ERK signaling in cultured
macrophages
Kallistatin contains two important structural elements:
an active site and a heparin-binding domain [28,29].
Kallistatin, via its heparin-binding site, has been shown
to inhibit TNF-α- and HMGB1-mediated inflammation in
cultured endothelial cells [21,25]. We therefore examined
the role of kallistatin’s structural elements in kallistatin-
induced SOCS3 expression in cultured macrophages.
SOCS3 expression was significantly increased by wild-type
kallistatin (1.9 ± 0.2 fold, n = 3, P <0.05) and heparin-
binding site mutant kallistatin (1.9 ± 0.1 fold, n = 3,
P <0.05), but not active site mutant kallistatin (n = 3,
P >0.05; Figure 7A). These results suggest that kallistatin,
via its active site, induces SOCS3 expression. Moreover,
kallistatin markedly induced SOCS3 expression more than
three-fold (KS: 3.1 ± 0.2 fold; n = 3, P <0.05), and the
effect was blocked by PD98059 (ERK inhibitor, 10 μM;
55 ± 5.2% reduction; n = 3, P <0.05), chelerythrine (PKCinhibitor, 1 μM; 73 ± 0.5% reduction; n = 3, P <0.05) and
genistein (tyrosine kinase inhibitor, 5 μM; 67 ± 3.0% re-
duction; n = 3, P <0.05; Figure 7B). However, kallistatin’s
effect on SOCS3 expression was not affected by LY294002
(PI3K inhibitor) or L-NAME (nitric oxide synthase
(NOS) inhibitor), indicating an event unrelated to the
PI3K-Akt-NOS pathway (data not shown). In addition,
kallistatin significantly increased ERK1/2 phosphorylation
(3.1 ± 0.5 fold, n = 3, P <0.05), which was reduced by
PD98059 (80 ± 3.0% reduction; n = 3, P <0.05), che-
lerythrine (45 ± 4.0% reduction; n = 3, P <0.05) and genis-
tein (55 ± 7.0% reduction; n = 3, P <0.05; Figure 7C). These
results indicate that kallistatin induces SOCS3 expression
via activating tyrosine kinase-PKC-ERK signaling.
Discussion
This is the first study to demonstrate that kallistatin
administration after onset of sepsis protects against
lethality and multi-organ damage in mouse models of
both polymicrobial infection and LPS-induced endo-
toxemia. Human kallistatin not only improved the
survival of mice with established sepsis, but also
significantly reduced organ injury in the kidney, lung and
liver. Kallistatin treatment markedly lowered systemic
inflammation as indicated by decreased circulating
levels of the pro-inflammatory cytokines TNF-α, IL-6 and
HMGB1. Our findings also indicate that kallistatin
dramatically upregulated SOCS3 expression, a negative
Figure 7 Kallistatin treatment enhances suppressor of cytokine signaling-3 (SOCS3) expression through activation of a tyrosine kinase-protein
kinase C (PKC)-extracellular signal-regulated kinase (ERK) signaling pathway in RAW264.7 cells. (A) Macrophages were incubated with 0.05 μM
wild-type kallistatin (WT-KS), heparin-mutant kallistatin (HM-KS) or active site-mutant kallistatin (AM-KS) for 12 hours. Wild-type or heparin mutant
kallistatin, but not active site mutant kallistatin, significantly increased SOCS3 expression (n = 3). (B) The effect of kallistatin on SOCS3 expression
in macrophages was blocked by PD98059 (PD; ERK inhibitor), chelerythrine (CHE; PKC inhibitor) and genistein (GEN; tyrosine kinase inhibitor).
(C) ERK phosphorylation induced by kallistatin in macrophages was also reversed by PD98059, chelerythrine and genistein (n = 3). *P <0.05
versus control group; #P <0.05 versus kallistatin alone.
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Moreover, kallistatin’s active site plays a crucial role
in inducing SOCS3 expression via activation of a tyro-
sine kinase-PKC-ERK pathway in cultured macrophages.
Our previous studies indicated that kallistatin, through its
heparin-binding site, blocks TNF-α and HMGB1-induced
inflammatory responses [21,25]. Collectively, these findings
reveal a protective role and unique mechanisms of kallista-
tin in mortality, systemic inflammation and multi-organ
damage in mice with established sepsis. Importantly, as
sepsis is the second leading cause of death in non-coronary
ICU patients [30], kallistatin may be a novel strategy for
combating sepsis syndrome in humans.
Severe sepsis is characterized by systemic inflammation,
organ damage and a high rate of mortality. The crucial
role of inflammatory cytokines in the pathogenesis of
sepsis has been convincingly demonstrated [7]. Numerous
cytokines and inflammatory mediators, including IL-1,
IL-6, IL-12 and TNF-α, are documented to be released inthe early phase of sepsis, while HMGB1 is released at the
late phase [7]. High serum concentrations of TNF-α are
correlated with sepsis-induced mortality [31]. It has also
been shown that blockade of IL-6 and HMGB1 increases
the survival of septic animals with established sepsis
[32,33]. Our present study shows that delayed admin-
istration of human kallistatin markedly attenuated
kidney, liver and lung injury in association with
reduced serum levels of TNF-α, IL-6 and/or HMGB1
in mice with established sepsis. Kallistatin, through its
heparin-binding site, inhibits TNF-α- and HMGB1-
induced inflammation by antagonizing their binding
to endothelial cell surfaces [21,25]. Therefore, kallistatin
can effectively lower both early and late phase systemic
inflammatory cytokine levels and their downstream
effects during sepsis. This suggests that the beneficial
effect of kallistatin on sepsis-induced organ injury
and mortality is mainly attributed to its inhibition of
inflammatory cytokine expression.
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sepsis as it is a negative regulator of LPS-induced
inflammation [34]. A previous report showed that
kallistatin protects against LPS-induced inflammation
and TNF-α production via upregulation of macrophage
SOCS3 expression [35]. Our current study also indicates
that kallistatin attenuated inflammation and organ injury
in association with increased SOCS3 expression in the
lung and kidney of mice with polymicrobial infection or
LPS-induced endotoxic shock. LPS and inflammatory
cytokines were shown to induce SOCS3 expression via
PKC-ERK or PI3K-ERK signaling [11]. Our results
indicate that kallistatin increased SOCS3 expression in
cultured macrophages via activation of a tyrosine
kinase-PKC-ERK signaling pathway, as kallistatin’s
effects on ERK phosphorylation and SOCS3 expression
were blocked by inhibitors of tyrosine kinase, PKC and
ERK1/2. Kallistatin’s effect on SOCS3 expression was not
affected by LY294002 or L-NAME, indicating an event
independent of the PI3K-Akt-NOS pathway (data not
shown). Kallistatin contains two structural elements:
an active site and a heparin-binding domain [28,29].
Kallistatin, via its heparin-binding site, interacts with
cell surface heparan sulfate, thus blocking the binding
of TNF-α or HMGB1 to their receptors and subsequent
inflammatory responses [21,25]. In the present study, we
showed that kallistatin, through its active site, stimulated
SOCS3 expression by activating a cell surface tyrosine
kinase, and thus PKC-ERK signaling. Therefore, kallistatin
protects against sepsis-induced inflammation, organ
damage and mortality by antagonizing TNF-α- and
HMGB1-mediated inflammatory gene expression, and by
inducing SOCS3 synthesis (Figure 8). Kallistatin wasFigure 8 Proposed mechanisms mediated by kallistatin in sepsis-induced inf
domain, antagonizes TNF-α- and HMGB1-mediated inflammatory gene expre
HMGB1, high mobility group box-1; SOCS3, suppressor of cytokine signaling-3shown to increase endothelial NOS expression and activa-
tion, and thus NO formation, leading to inhibition of vas-
cular inflammation [20,36]. Taken together, these findings
indicate that kallistatin is a unique anti-inflammatory
agent by modulating differential signaling pathways.
LPS stimulates expression of SOCS3, which in turn
negatively regulates LPS-induced TLR signaling [8,34].
TLRs elicit systemic inflammatory responses and contribute
to organ injury and high mortality in animal models of sep-
sis [37]. TLR2 and TLR4 expression are increased in septic
patients, and inhibition of TLR signaling and expression
was shown to improve the survival of septic mice [38].
TLR4 is considered to be the main receptor mediating the
inflammatory activity of HMGB1 [39]. Kallistatin pre-
treatment was found to reduce TLR4 expression in the
lungs and kidneys of CLP mice [25]. The present study also
shows that delayed kallistatin administration decreased
sepsis-induced TLR4 expression in the lung and liver.
Therefore, kallistatin most likely modulates TLR signaling
and expression through induction of SOCS3 synthesis,
leading to protection against sepsis-induced inflammatory
response and organ injury.
Dysfunction of the kidney, lung and liver are common
morbidities associated with sepsis [40]. Interestingly, the
kallistatin gene (SERPINA4) is strongly correlated with a
decreased risk of developing acute kidney injury in
patients with septic shock [41]. Herein, we show that
administration of kallistatin after onset of sepsis improved
kidney and liver dysfunction in mouse models with poly-
microbial infection and LPS injection. Moreover, delayed
kallistatin treatment suppressed oxidative stress in the
lung as indicated by reduced MDA levels in CLP mice.
Oxidative stress activates inflammatory pathways andlammation, organ injury and mortality. Kallistatin, via its heparin-binding
ssion, and its active site is essential for inducing SOCS3 expression.
; TNF-α, tumor necrosis factor-α.
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Thus, these findings indicate that kallistatin protects
against sepsis-induced organ injury through reduction
of oxidative stress and inflammation. In addition to
preventing established sepsis-induced organ injury,
kallistatin gene delivery or kallistatin protein treatment
has been shown to improve survival in various animal
models [23-25,35]. Transgenic mice overexpressing
kallistatin were more resistant to Gram-negative E.
coli LPS-induced mortality [23]. Moreover, kallistatin
gene transfer increased survival and reduced liver and
skin injury, as well as inflammation, in mice with
Gram-positive streptococcal infection [24]. Furthermore,
kallistatin (kallikrein-binding protein) pre-treatment at
two hours before LPS injection was observed to improve
the survival of endotoxemic mice [35]. Likewise, we
recently reported that kallistatin pre-treatment reduced
mortality in septic mice after CLP surgery [25]. Importantly,
the present study demonstrates that delayed administration
after onset of sepsis significantly improves the survival
of mice with polymicrobial infection and endotoxemia.
Therefore, kallistatin could be a promising new agent for
the treatment of sepsis.
Conclusions
This study demonstrated that delayed human kallistatin
treatment after onset of sepsis reduces inflammation,
organ injury and mortality in both septic mouse models
with polymicrobial infection and endotoxic shock.
Moreover, this is the first study to indicate that kallistatin’s
active site plays a key role in stimulating SOCS3 expression
via tyrosine kinase-PKC-ERK signaling in immune cells. As
kallistatin is an endogenous molecule, kallistatin therapy
may lead to the protection and/or reversal of sepsis-
induced injury. The unique anti-inflammatory actions
of kallistatin need to be further explored as a novel
therapeutic approach for sepsis.
Key messages
 Delayed administration of human kallistatin reduced
organ damage, inflammation and lethality in mouse
models of polymicrobial infection and
lipopolysaccharide-induced endotoxemia.
 Kallistatin treatment attenuated established
sepsis-induced inflammation and multi-organ injury
in association with reduced TNF-α and HMGB1
expression, as well as increased SOCS3 synthesis.
 Kallistatin’s active site is essential for inducing
SOCS3 expression by activation of tyrosine
kinase-PKC-ERK signaling.
 Kallistatin is a unique anti-inflammatory agent with
pleiotropic actions, leading to significant protection
against established sepsis.Abbreviations
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